Clinical trial results in Acute Respiratory Distress Syndrome (ARDS) supported Fast Track designation by FDA and designation by the Biomedical Advanced Research and Development Authority (BARDA) as a "Highly Relevant" program for COVID-19 and other pathogens

Learn More

Athersys comments on misleading article authored by a hedge fund

Read Here

Who We Are

Our Focus

Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our focus is on the treatment of medical conditions where there is significant clinical need, and we are particularly focused on developing therapies in the regenerative medicine area.

We are developing MultiStem®, a patented, adult-derived "off-the-shelf" stem cell therapy platform, for disease indications in areas of neurological, inflammatory & immune, and cardiovascular disease areas, as well as other critical care indications where there is substantial unmet medical need due to the limitations in standard of care.

Learn More

Featured Video

Latest News

All News